Medidata Solutions (NASDAQ:MDSO) was downgraded by stock analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a note issued to investors on Tuesday.
Several other equities research analysts have also issued reports on the stock. Zacks Investment Research lowered shares of Medidata Solutions from a “hold” rating to a “sell” rating in a report on Thursday, April 12th. ValuEngine lowered shares of Medidata Solutions from a “hold” rating to a “sell” rating in a report on Saturday, March 17th. Piper Jaffray Companies lifted their price target on shares of Medidata Solutions to $98.00 and gave the company an “overweight” rating in a report on Wednesday, May 23rd. Morgan Stanley lowered shares of Medidata Solutions from an “overweight” rating to a “hold” rating and set a $79.00 price target on the stock. in a report on Monday, May 21st. Finally, Deutsche Bank lifted their price target on shares of Medidata Solutions from $78.00 to $85.00 and gave the company a “buy” rating in a report on Thursday, May 31st. One research analyst has rated the stock with a sell rating, five have issued a hold rating and eleven have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $86.07.
Shares of Medidata Solutions opened at $79.90 on Tuesday, MarketBeat.com reports. The company has a market cap of $4.88 billion, a P/E ratio of 94.00, a P/E/G ratio of 5.29 and a beta of 1.50. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.63 and a current ratio of 1.63. Medidata Solutions has a 1 year low of $59.60 and a 1 year high of $85.92.
Medidata Solutions (NASDAQ:MDSO) last announced its quarterly earnings results on Thursday, April 19th. The company reported $0.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.35 by $0.05. The company had revenue of $149.20 million for the quarter, compared to analyst estimates of $146.73 million. Medidata Solutions had a net margin of 7.96% and a return on equity of 11.36%. The firm’s revenue was up 16.9% on a year-over-year basis. During the same period in the previous year, the firm posted $0.31 EPS. equities research analysts forecast that Medidata Solutions will post 0.76 EPS for the current year.
In other Medidata Solutions news, CFO Rouven Bergmann sold 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 19th. The shares were sold at an average price of $82.85, for a total transaction of $248,550.00. Following the sale, the chief financial officer now directly owns 81,642 shares of the company’s stock, valued at approximately $6,764,039.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Michael I. Otner sold 10,395 shares of the business’s stock in a transaction that occurred on Wednesday, April 25th. The stock was sold at an average price of $70.05, for a total transaction of $728,169.75. Following the sale, the executive vice president now directly owns 74,165 shares in the company, valued at $5,195,258.25. The disclosure for this sale can be found here. Insiders have sold a total of 24,025 shares of company stock worth $1,774,961 over the last three months. Insiders own 4.70% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of MDSO. Meadow Creek Investment Management LLC lifted its position in shares of Medidata Solutions by 31.4% in the 4th quarter. Meadow Creek Investment Management LLC now owns 3,680 shares of the company’s stock worth $233,000 after purchasing an additional 880 shares during the period. Asset Management One Co. Ltd. lifted its position in shares of Medidata Solutions by 102.7% in the 1st quarter. Asset Management One Co. Ltd. now owns 3,948 shares of the company’s stock worth $248,000 after purchasing an additional 2,000 shares during the period. Joel Isaacson & Co. LLC acquired a new position in shares of Medidata Solutions in the 1st quarter worth approximately $314,000. Elkfork Partners LLC acquired a new position in shares of Medidata Solutions in the 4th quarter worth approximately $408,000. Finally, Diversified Trust Co lifted its position in shares of Medidata Solutions by 26.2% in the 1st quarter. Diversified Trust Co now owns 6,500 shares of the company’s stock worth $408,000 after purchasing an additional 1,350 shares during the period.
Medidata Solutions Company Profile
Medidata Solutions, Inc provides cloud-based solutions for life sciences worldwide. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development of new therapies. The company's platform solutions include data capture and management and trial planning and management.
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.